BGCS Abstract Submission

Abstract submission is now closed.

We are delighted to announce the following winners:

Best Oral Presentation – Popular Vote (through Conference App):

O – 5
LONG TERM RESULTS FROM RT3VIN: A MULTI-CENTRE, RANDOMISED, PHASE II TRIAL OF CIDOFOVIR OR IMIQUIMOD TREATMENT FOR VULVAL INTRAEPITHELIAL NEOPLASIA 3
Jones S1, Hurt C4, Madden T4, Fiander A1, Nordin A2, Naik R3, Powell N1, Tristram A1
1Cardiff University, Cardiff, United Kingdom, 2East Kent Gynaecological Oncology Centre, Queen Elizabeth the Queen Mother Hospital, Margate, United Kingdom, 3Northern Gynaecology Oncology Centre, Queen Elizabeth Hospital, Gateshead, United Kingdom, 4Wales Cancer Trials Unit, Cardiff Univeristy, Cardiff, United Kingdom

Best Oral Presentation – Judges’ Vote:

O – 8
INHIBITION OF MATERNAL EMBRYONIC LEUCINE-ZIPPER KINASE IS A NOVEL THERAPY FOR NON-UTERINE PELVIC HIGH GRADE SEROUS CARCINOMA.
McDermott C1, Beirne J1,2, Lyons-Ewing D1, Feeney L1, Buckley N1, McArt D3, Roddy A3, McCabe N1, Salto-Tellez M4, Kennedy R1, Harley I1,2, McCluggage W5, Mullan P1
1Centre For Cancer Research And Cell Biology, Queen’s University, Belfast, Belfast, United Kingdom, 2Northern Ireland Centre for Gynaecological Cancer, Belfast City Hospital, Belfast, United Kingdom, 3Department of Cancer Bioinformatics, Queen’s University, Belfast, United Kingdom, 4Northern Ireland Molecular Pathology Laboratory, Belfast, United Kingdom, 5Department of Pathology, Royal Victoria Hospital, Belfast, United Kingdom

Best Poster –┬áPopular Vote (through Conference App):

P – 21
PATIENT TRIGGERED FOLLOW UP FOR ENDOMETRIAL CARCINOMA: THE SOUTHAMPTON EXPERIENCE FROM 2013 TO 2016
Pontefract D1, Crawford S1
1University Hospital Southampton Gynaecological Oncology Group, Southampton, United Kingdom

Best Poster – Judges’ Vote:

P – 25
COST-EFFECTIVENESS OF POPULATION BASED BRCA TESTING WITH VARYING ASHKENAZI JEWISH ANCESTRY
Manchanda R1,2, Patel S1,3, Antoniou A4, Levy-Lahad E5, Turnbull C6, Evans G7, Hopper J8, MacInnis R9, Menon U10, Jacobs I11, Legood R3
1Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, United Kingdom, 2Department of Gynaecological Oncology, Bartshealth NHS Trust, Royal London Hospital, United Kingdom, 3Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, United Kingdom, 4Centre for Cancer Genetic Epidemiology, University of Cambridge, United Kingdom, 5Medical Genetics Institute, Shaare Zedek Hospital, Jerusalem, Israel, 6Barts Cancer Institute, Queen Mary University of London, United Kingdom, 7Centre for Genomic Medicine, Division of Evolution and Genomic Science, University of Manchester, United Kingdom, 8Centre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, University of Melbourne, Australia, 9Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Australia, 10Gynaecological Cancer Research Centre, Department of Women’s Cancer, Institute for Women’s Health, University College London, United Kingdom, 11University of New South Wales, Australia

Best Poster – Judges Vote:

P – 54
RISK FACTOR ANALYSIS OF RECURRENCE IN LOW RISK EARLY STAGE ENDOMETRIAL CARCINOMA: THE POTENTIAL PREDICTIVE ROLE OF THE HYPERTENSIVE COMPONENT OF THE METABOLIC SYNDROME
Romano F1, Laios A1, Limura E1, Attygalle A3, Taylor A2, Lalondrelle S2, Butler J1, Nobbenhuis M1, Barton D1, Ind T1
1Department of Gynaecological Oncology, The Royal Marsden Hospital, Fulham Road, SW36JJ, London, UK, London, United Kingdom, 2Department of Medical Oncology, The Royal Marsden Hospital, Fulham Road, SW36JJ, London, UK, London, United Kingdom, 3Department of Pathology, The Royal Marsden Hospital, Fulham Road, SW36JJ, London, UK, London, United Kingdom